Advertisement

Allergic Rhinitis

  • Margaret Redmond
Chapter

Abstract

This chapter discusses allergic rhinitis and conjunctivitis which are very common chronic illnesses in adolescence. Differential diagnosis and historical clues to make diagnosis in allergic rhinitis and conjunctivitis are reviewed. The importance and methods of making correct diagnosis and identification of relevant allergens are examined. The evidence to support recommended avoidance strategies and medical management are reviewed. Special consideration is given to adolescent patients in avoiding common pitfalls and finding a successful management strategy.

Keywords

Allergic rhinitis Allergic conjunctivitis Chronic rhinitis Intranasal steroids Antihistamines Immunotherapy 

References

  1. 1.
    Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122:s1–84.PubMedCrossRefGoogle Scholar
  2. 2.
    Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–43.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    CDC. CDC National Health Interview Survey. 2014.Google Scholar
  4. 4.
    Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol. 2007;120(2):381–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol. 1994;93(2):413–23.PubMedCrossRefGoogle Scholar
  6. 6.
    Valls-Mateus M, Marino-Sanchez F, Ruiz-Echevarría K, et al. Nasal obstructive disorders impair health-related quality of life in adolescents with persistent allergic rhinitis: a real-life study. Pediatr Allergy Immunol. 2017;28:438–45.PubMedCrossRefGoogle Scholar
  7. 7.
    Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445–54.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Hawrylowicz CM, O’Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol. 2005;5(4):271–83.PubMedCrossRefGoogle Scholar
  9. 9.
    Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008. Allergy. 2008;63:8–160.PubMedCrossRefGoogle Scholar
  10. 10.
    Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol. 2010;126(4):778–83.PubMedCrossRefGoogle Scholar
  11. 11.
    Williams DC, Edney G, Maiden B, Smith PK. Recognition of allergic conjunctivitis in patients with allergic rhinitis. World Allergy Organ J. 2013;6(1):4.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Hasegawa M, Kern EB. The human nasal cycle. Mayo Clin Proc. 1977;52(1):28–34.PubMedGoogle Scholar
  13. 13.
    Alm B, Goksör E, Thengilsdottir H, Pettersson R, Möllborg P, Norvenius G, Erdes L, Aberg N, Wennergren G. Early protective and risk factors for allergic rhinitis at age 4½ yr. Pediatr Allergy Immunol. 2011;22:398–404.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Illi S, Weber J, Zutavern A, Genuneit J, Schierl R, Strunz-Lehner C, von Mutius E. Perinatal influences on the development of asthma and atopy in childhood. Ann Allergy Asthma Immunol. 2014;112:132–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Zizka LH, Beggs PJ. Anthropogenic climate change and allergen exposure: the role of plant biology. J Allergy Clin Immunol. 2012;129(1):27–32.CrossRefGoogle Scholar
  16. 16.
    Juliusson S, Bende M. Priming effect of a birch pollen season studied with laser Doppler flowmetry in patients with allergic rhinitis. Clin Allergy. 1988;18:615–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Wachs M, Proud D. Observations on the pathogenesis of nasal priming. J Allergy Clin Immunol. 1989;84:492–501.PubMedCrossRefGoogle Scholar
  18. 18.
    Vrcek I, Ozgur O, Nakra T. Infraorbital dark circles: a review of the pathogenesis, evaluation and treatment. J Cutan Aesthet Surg. 2016;9(2):65–72.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Wright AL, Holberg CJ, Martinez FD, Halonen M, Morgan W, Taussig LM. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics. 1994;94:895–901.PubMedGoogle Scholar
  20. 20.
    Pastorello EA, Codecasa LR, Pravettoni V, et al. Clinical reliability of diagnostic tests in allergic rhinoconjunctivitis. Boll 1st Sieroter Milan. 1988;67(5–6):377–85.Google Scholar
  21. 21.
    Krouse JH, Sadrazodi K, Kerswill K. Sensitivity and specificity of prick and intradermal testing in predicting response to nasal provocation with timothy grass antigen. Otolaryngol Head Neck Surg. 2004;131(3):215–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Nielsen JS, Meteran H, Suppli Ulrik C, Porsbjerg C, Backer V. Natural history of skin prick reactivity: a 20-year prospective study of a random population sample of children and adolescents. Ann Allergy Asthma Immunol. 2017;119(2):1840188.Google Scholar
  23. 23.
    Bernstein IL, Li JT, Bernstein DI, Hamilton R, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100(3 Suppl 3):S1–148.PubMedGoogle Scholar
  24. 24.
    Lockey RF, Benedict LM, Turkeltaub PC, et al. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987;79:660–77.PubMedCrossRefGoogle Scholar
  25. 25.
    Solomon WR, Burge HA, Boise JR. Exclusion of particulate allergens by window air conditioners. J Allergy Clin Immunol. 1980;65(4):305–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Barnes C, Pacheco F, Landuyt J, Hu F, Portnoy J. Hourly variation of airborne ragweed pollen in Kansas City. Ann Allergy Asthma Immunol. 2001;86:166–71.PubMedCrossRefGoogle Scholar
  27. 27.
    Jones AM, Harrison RM. The effects of meteorological factors on atmospheric bioaerosol concentrations—a review. Sci Total Environ. 2004;326(1):151–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Kenney P, Hilberg O, Sigsgaard T. Clinical application of nasal filters: an observational study on the usability of nasal filters in managing seasonal allergic rhinitis. J Allergy Clin Immunol Pract. 2016;4(3):445–452.e4.PubMedCrossRefGoogle Scholar
  29. 29.
    Comert S, Karakaya G, Kalyoncu AF. Wraparound eyeglasses improve symptoms and quality of life in patients with seasonal allergic rhinoconjunctivitis. Int Forum Allergy Rhinol. 2016;6(7):722–30.PubMedCrossRefGoogle Scholar
  30. 30.
    Burch M, Levetin E. Effects of meteorological conditions on spore plumes. Int J Biometeorol. 2002;46:107–17.PubMedCrossRefGoogle Scholar
  31. 31.
    Rodriguez-Rajo FJ, Iglesias I, Jato V. Variation assessment of airborne Alternaria and Cladosporium spores at different bioclimatical conditions. Mycol Res. 2005;109:497–507.PubMedCrossRefGoogle Scholar
  32. 32.
    Peternel R, Culig J, Hrga I. Atmospheric concentrations of Cladosporium spp. and Alternaria spp. spores in Zagreb (Croatia) and effects of some meteorological factors. Ann Agric Environ Med. 2004;11:303–7.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Kusaka H, Ogasawara H, Munakata M, Tanimura K, Ukita H, Denzumi N, et al. Two-year follow up on the protective value of dust masks against farmer’s lung disease. Intern Med. 1993;32:106–11.PubMedCrossRefGoogle Scholar
  34. 34.
    Sauni R, Verbeek JH, Uitti J, Jauhiainen M, Kreiss K, Sigsgaard T. Remediating buildings damaged by dampness and mould for preventing or reducing respiratory tract symptoms, infections and asthma. Cochrane Database Syst Rev. 2015;2:CD007897.Google Scholar
  35. 35.
    Arbes SJ, Cohn RD, Yin M, Muilenburg ML, Burge HA, Friedman W, Zeldin DC. Dog allergen (Can f 1) and cat allergen (Fel d 1) in US homes: results from the National Survey of Lead and Allergens in Housing. J Allergy Clin Immunol. 2004;114(1):111–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Egmar AC, Almqvist C, Emenius G, Lilja G, Wickman M. Deposition of cat (Fel d 1), dog (Can f 1), and horse allergen over time in public environments--a model of dispersion. Allergy. 1998;53(10):957–61.PubMedCrossRefGoogle Scholar
  37. 37.
    Vredegoor DW, Willense T, Chapman MD, Heederik DJJ, Krop EJM. Can f 1 levels in hair and homes of different dog breeds: lack of evidence to describe any dog breed as hypoallergenic. J Allergy Clin Immunol. 2012;130:904–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Shirai T, Matsui K, Suzuki K, Chida K. Effect of pet removal on pet allergic asthma. Chest. 2005;127:1565–71.PubMedCrossRefGoogle Scholar
  39. 39.
    Nageotte C, Park M, Havstad S, Zoratti E, Ownby D. Duration of airborne Fel D 1 reduction after cat washing. J Allergy Clin Immunol. 2006;118:521–2.PubMedCrossRefGoogle Scholar
  40. 40.
    Arlian LG, Neal JS, Morgan MS, Rapp CM, Clobes AL. Distribution and removal of cat, dog, and mite allergens on smooth surfaces in homes with and without pets. Ann Allergy Asthma Immunol. 2001;87:296–302.PubMedCrossRefGoogle Scholar
  41. 41.
    Wood RA, Johnson EF, Van Natta ML, Chen PH, Eggleston PA. A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy. Am J Respir Crit Care Med. 1998;158(1):115–20.PubMedCrossRefGoogle Scholar
  42. 42.
    Portnoy J, Kennedy K, Sublett J, et al. Environmental assessment and exposure control: a practice parameter-furry animals. Ann Allergy Asthma Immunol. 2012;108(4):223 e.1–15.CrossRefGoogle Scholar
  43. 43.
    Phipatanakul W, Cronin B, Wood RA, et al. Effect of environmental intervention on mouse allergen levels in homes of inner-city Boston children with asthma. Ann Allergy Asthma Immunol. 2004;92:420–5.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Wilson J, Dixon SL, Breysse P, Jacobs D, Adamkiewicz G, Chew GL, Dearborn D, Krieger J, Sandel M, Spanier A. Housing and allergens: a pooled analysis of nine US studies. Environ Res. 2010;110(2):189–98.PubMedCrossRefGoogle Scholar
  45. 45.
    Morgan WJ, Crain EF, Gruchalla RS, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med. 2004;351:1068–80.PubMedCrossRefGoogle Scholar
  46. 46.
    Sever ML, Arbes SJ, Gore JC, et al. Cockroach allergen reduction by cockroach control alone in low-income urban homes: a randomized control trial. J Allergy Clin Immunol. 2007;120:849–55.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Arbes SJ, Sever M, Mehta J, Collette N, Thomas B, Zeldin DC. Exposure to indoor allergens in day-care facilities: results from 2 North Carolina counties. J Allergy Clin Immunol. 2005;116(1):133–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Arbes SJ, Cohn RD, Yin M, Muilenburg ML, Burge HA, Friedman W, Zeldin DC. House dust mite allergen in US beds: results from the first national survey of lead and allergens in housing. J Allergy Clin Immunol. 2003;111(2):408–14.PubMedCrossRefGoogle Scholar
  49. 49.
    Tovey ER, Taylor DJ, Mitakakis TZ, De Lucca SD. Effectiveness of laundry washing agents and conditions in the removal of cat and dust mite allergen from bedding dust. J Allergy Clin Immunol. 2001;108:369–74.PubMedCrossRefGoogle Scholar
  50. 50.
    Luczynska C, Tredwell E, Smeeton N, Burney P. A randomized controlled trial of mite allergen-impermeable bed covers in adult mite-sensitized asthmatics. Clin Exp Allergy. 2003;33(12):1648–53.PubMedCrossRefGoogle Scholar
  51. 51.
    Reddel HK, Bateman ED, Becker A et al. Global strategy for asthma management and prevention. Available from: https://ginasthma.org/wp-content/uploads/2016/01/GINA_Report_2015_Aug11-1pdf. Updated 2015.
  52. 52.
    Nurmatov U, van Schayck CP, Hurwitz B, Sheikh A. House dust mite avoidance measures for perennial allergic rhinitis: an updated Cochrane systematic review. Allergy. 2012;67:158–65.PubMedCrossRefGoogle Scholar
  53. 53.
    Dilley MA, Phipatanakul W. Environmental control measures for the management of atopy. Ann Allergy Asthma Immunol. 2017;118(2):154–60.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Wang YH, Yang CP, Ku MS, Sun HL, Lue KH. Efficacy of nasal irrigation in the treatment of acute sinusitis in children. Int J Pediatr Otorhinolaryngol. 2009;73(12):1696–701.PubMedCrossRefGoogle Scholar
  55. 55.
    Li H, Sha Q, Zuo K, Jiang H, Cheng L, Shi J, Xu G. Nasal saline irrigation facilitates control of allergic rhinitis by topical steroid in children. J Otorhinolaryngol Relat Spec. 2009;71(1):50–5.CrossRefGoogle Scholar
  56. 56.
    Chen JR, Jin L, Li XY. The effectiveness of nasal saline irrigation (seawater) in treatment of allergic rhinitis in children. Int J Pediatr Otorhinolaryngol. 2014;78(7):1115–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Louisiana Department of Health and Hospitals. http://new.dhh.louisiana.gov/index.cfm/newsroom/detail/2332. Last accessed 29 Sept 2017.
  58. 58.
    Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomized control trials. BMJ. 1998;317(7173):1624–9.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Church MK, Maurer M, Simons FER, Bindslev-Jensen C, Van Cauwenberge P, Bousquet J, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65:459–66.PubMedCrossRefGoogle Scholar
  60. 60.
    Tsujii T, Yamamoto E, Ohira T, Takahasi T, Watanabe S. Antihistamine effects of prefrontal cortex activity during working memory process in preschool children: a near-infrared spectroscopy (NIRS) study. Neurosci Res. 2010;67(1):80–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Vuurman EF, van Veggel LM, Uiterwijk MM, Leutner D, O’Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children’s learning. Ann Allergy. 1993;71(2):121–6.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Tzanetos DB, Fahrenholz JM, Scott T, Buchholz K. Comparison of sedating effects of levocetirizine and cetirizine: a randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2011;107(6):517–22.PubMedCrossRefGoogle Scholar
  63. 63.
    Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with “non-sedating” antihistamines: four prescription-event monitoring studies in general practice. BMJ. 2000;320(7243):1184–6.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Layton D, Wilton L, Boshier A, Cornelius V, Harris S, Shakir SA. Comparison of risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf. 2006;29(10):897–909.PubMedCrossRefGoogle Scholar
  65. 65.
    Kaszuba SM, Baroody FM, de Tineo M, Haney L, Blair C, Naclerio RM. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med. 2001;161(21):2581–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Juel-Berg N, Darling P, Bolvig J, Foss-Skiftesvik MH, Hlaken S, Winther L, Hansen KS, Askjaer N, Heegaard S, Madsen AR, Opstrup MS. Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: a systematic review and meta-analysis. Am J Rhinol Allergy. 2017;31(1):19–28.PubMedCrossRefGoogle Scholar
  67. 67.
    Berger WE, Kaiser H, Gawchik SM, Tillinghast J, Woodworth TH, Dupclay L, Georges GC. Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis. Otolaryngol Head Neck Surg. 2003;129(1):16–23.PubMedCrossRefGoogle Scholar
  68. 68.
    Mandi M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group. Ann Allergy Asthma Immunol. 1997;79(3):237–45.Google Scholar
  69. 69.
    Karaki M, Akiyama K, Mori N. Efficacy of intranasal steroid spray (mometasone furoate) on treatment of patients with seasonal allergic rhinitis: comparison with oral steroids. Auris Nasus Larynx. 2013;40(3):227–81.CrossRefGoogle Scholar
  70. 70.
    Higaki T, Okano M, Makihara S, Fujiwara T, Haruna T, Noda Y, Kariya S, Nishizaki K. Early interventional treatment with intranasal corticosteroids compared with post-onset treatment in pollinosis. Ann Allergy Asthma Immunol. 2012;109(6):458–64.PubMedCrossRefGoogle Scholar
  71. 71.
    Bruni FM, DeLuca G, Venturoli V, Boner AL. Intranasal corticosteroids and adrenal suppression. Neuroimmunodulation. 2009;16(5):353–62.CrossRefGoogle Scholar
  72. 72.
    Lee LA, Sterling R, Maspero J, Clements D, Ellsworth A, Pedersen S. Growth velocity reduced with once daily fluticasone furoate nasal spray in prepubescent children with perennial allergic rhinitis. J Allergy Clin Immunol Pract. 2014;2(4):421–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Lee TA, Pickard AS. Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. Pharmacotherapy. 2007;27(6):852–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Berger W, Hampel F Jr, Bernstein J, Shah S, Sacks H, Meltzer EO. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97(3):375–81.PubMedCrossRefGoogle Scholar
  75. 75.
    Shah SR, Nayak A, Ratner P, Roland P, Michael Wall G. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active-and placebo-controlled study in adolescents and adults. Clin Ther. 2009;31(1):99–107.PubMedCrossRefGoogle Scholar
  76. 76.
    Ratner P, Hampel F, Van Bavel J, Amar N, Daftary P, Wheeler W, Sacks H. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008;100(1):74–81.PubMedCrossRefGoogle Scholar
  77. 77.
    Kaliner M. Azelastine and olopatadine in treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2009;103(5):373–80.PubMedCrossRefGoogle Scholar
  78. 78.
    Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. Investig Allergol Clin Immunol. 2006;16:148–55.Google Scholar
  79. 79.
    Vaidynathan S, Williamson P, Clearie K, Khan F, Lipworth B. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med. 2010;182(1):19–24.CrossRefGoogle Scholar
  80. 80.
    Welsh PW, Stricker WE, Chu CP, Naessens JM, Reese ME, Reed CE, Marcoux JP. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in reliving symptoms of ragweed allergy. Mayo Clin Proc. 1987;62(2):125–34.PubMedCrossRefGoogle Scholar
  81. 81.
    Milgrom H, Biondi R, Georgitis JW, Meltzer EO, Munk ZM, Drda K, Wood CC. Comparison of ipratropium bromide 0.3% with beclomethasone dipropionate in the treatment of perennial rhinitis in children. Ann Allergy Asthma Immunol. 1999;83(2):105–11.PubMedCrossRefGoogle Scholar
  82. 82.
    Cingi C, Gunhan K, Gage-White L, Unlu H. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope. 2010;120(9):1718–23.PubMedCrossRefGoogle Scholar
  83. 83.
    Ratner P, Van Bavel J, Mohar D, Jacobs RL, Hampel F, Howland W, Karwal R. Efficacy of daily intranasal fluticasone propionate on ocular symptoms associated with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2015;114(2):141–7.PubMedCrossRefGoogle Scholar
  84. 84.
    Greiner JV, Michaelson C, McWhirter CL, Shams NB. Single dose of ketotifen fumarate 0.025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitis. Adv Ther. 2002;19(4):185–93.PubMedCrossRefGoogle Scholar
  85. 85.
    Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol. 1994;94(1):134.PubMedCrossRefGoogle Scholar
  86. 86.
    Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1–55.PubMedCrossRefGoogle Scholar
  87. 87.
    Maloney J, Bernstein DI, Nelson H, Creticos P, Hebert J, Noonan M, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):146–53 e2.PubMedCrossRefGoogle Scholar
  88. 88.
    Halken S, Agertoft L, Seidenberg J, Bauer CP, Payot F, Martin-Munoz MF, et al. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. Pediatr Allergy Immunol. 2010;21(6):970–6.PubMedCrossRefGoogle Scholar
  89. 89.
  90. 90.
    Maloney J, Prenner BM, Bernstein DI, Lu S, Gawchik S, Berman G, et al. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites. Ann Allergy Asthma Immunol. 2016;116(1):59–65.PubMedCrossRefGoogle Scholar
  91. 91.
    Jacobsen L, Niggemann B, Dreborg S, Ferdous HA, Halken S, Host A, Kiovikko A, Norberg LA, Valovirta E, Wahn U, Moller C. Specific immunotherapy has long-term preventative effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943–38.PubMedCrossRefGoogle Scholar
  92. 92.
    Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251–6.PubMedCrossRefGoogle Scholar
  93. 93.
    Purello-D’Ambrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P, Parmiani S, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy. 2001;31(8):1295–302.PubMedCrossRefGoogle Scholar
  94. 94.
    Lourenço EA, et al. Subcutaneous immunotherapy improves the symptomatology of allergic rhinitis. Int Arch Otorhinolaryngol. 2016;20(1):6–12.PubMedCrossRefGoogle Scholar
  95. 95.
    Poddighe D, Licari A, Caimmi S, Marseglia GL. Sublingual immunotherapy for pediatric allergic rhinitis: the clinical evidence. World J Clin Pediatr. 2016;5(1):47–56.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;1:CD001936.Google Scholar
  97. 97.
    Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011;66(6):740–52.PubMedCrossRefGoogle Scholar
  98. 98.
    Chelladurai Y, Suarez-Cuervo C, Erekosima N, Kim JM, Ramanathan M, Segal JB, Lin SY. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic Rhinoconjunctivitis and asthma: a systematic review. J Allergy Clin Immunol Pract. 2013;1(4):361–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol. 2006;117(2):263–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2008;121(2):512–8 e2.PubMedCrossRefGoogle Scholar
  101. 101.
    Kim JM, Lin SY, Suarez-Cuervo C, Chelladurai Y, Ramanathan M, Segal JB, Erekosima N. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics. 2013;131:1155–67.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Rodriguez Perez N, Ambriz Moreno Mde J. Safety of immunotherapy and skin tests with allergens in children younger than five years (Inocuidad de la inmunoterapia y pruebas cutaneas con alergenos en ninos menores de cinco anos de edad). Rev Alerg Mex. 2006;53(2):47–51.PubMedGoogle Scholar
  103. 103.
    Finegold I. Immunotherapy: when to initiate treatment in children. Allergy Asthma Proc. 2007;28(6):698–705.PubMedCrossRefGoogle Scholar
  104. 104.
    Coop CA, Tankersley MS. Patient perceptions regarding local reactions from allergen immunotherapy injections. Ann Allergy Asthma Immunol. 2008;101(1):96–100.PubMedCrossRefGoogle Scholar
  105. 105.
    Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;118(2):434–40.PubMedCrossRefGoogle Scholar
  106. 106.
    Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the world allergy organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol. 2010;125(3):569–74, 74 e1-74 e7.PubMedCrossRefGoogle Scholar
  107. 107.
    Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol. 1989;83(4):797–802.PubMedCrossRefGoogle Scholar
  108. 108.
    Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol. 1993;92(1 Pt 1):6–15.PubMedCrossRefGoogle Scholar
  109. 109.
    Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J Allergy Clin Immunol. 2004;113(6):1129–36.PubMedCrossRefGoogle Scholar
  110. 110.
    Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: national surveillance study on allergen immunotherapy (2008–2013). Ann Allergy Asthma Immunol. 2016;116(4):354–359.e2.PubMedCrossRefGoogle Scholar
  111. 111.
    Kopp MV, Brauburger J, Riedinger F, Beischer D, Ihorst G, Kamin W, et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;110(5):728–35.PubMedCrossRefGoogle Scholar
  112. 112.
    Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol. 2007;120(3):688–95.PubMedCrossRefGoogle Scholar
  113. 113.
    Hankin CSCL, Bronstone A, Wang Z. Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2013;131(4):1084–91.PubMedCrossRefGoogle Scholar
  114. 114.
    Hankin CS, Cox L, Lang D, Levin A, Gross G, Eavy G, Meltzer E, Burgoyne D, Bronstone A, Wang Z. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol. 2008;121(1):227–32.PubMedCrossRefGoogle Scholar
  115. 115.
    Hankin CS, Cox L, Lang D, Bronstone A, Fass P, Leatherman B, Wang Z. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol. 2010;104:79–85.PubMedCrossRefGoogle Scholar
  116. 116.
    Tay SY, Chao SS, Mark KT, Wang Y. Comparison of the distribution of intranasal steroid spray using different application techniques. Int Forum Allergy Rhinol. 2016;6(11):1204–10.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Allergy and ImmunologyNationwide Children’s HospitalColumbusUSA
  2. 2.Department of PediatricsThe Ohio State University College of MedicineColumbusUSA

Personalised recommendations